>RESPONSIBILITY >CSR in Takeda
The core rationale for CSR at Takeda is in the corporate mission of "striving towards better health for patients worldwide through leading innovation in medicine." We believe it is important to recognize the various effects on society of the pharmaceutical business value chain. We therefore strive to maintain and improve sound business processes throughout our operations, and to engage in activities to promote a sustainable society as a good corporate citizen.
We entered the United Nations Global Compact in 2009, and have learned about the universal principles that leading global companies should observe. Since 2010, we have referred to ISO 26000, the international guidance standard for social responsibility, as the basis for implementing specific CSR activities.
We have traditionally used Global Reporting Initiative (GRI) Guidelines as a reference for our CSR disclosures. From 2011, Takeda also joined the International Integrated Reporting Council (IIRC) Pilot Program to try new ways of providing integrated disclosure of financial and non-financial information in line with IIRC principles. Furthermore, we are promoting deeper dialogue with stakeholders based on the AA1000 scheme. In seeking new ways to improve, we aim to enhance our CSR activities to respond to the demands of the international community.
In undertaking our CSR activities, we aim to build on the traditional "corporate action" approach, which is based on firms acting unilaterally, to develop a "collective action" approach in which we work in partnership with Takeda's stakeholders. In addition, we are developing a holistic approach to CSR where we try to maximize opportunities for creating value of society and enterprise. This approach entails taking a holistic perspective on "producer-type" activities involving other stakeholders, such as CSR-related advocacy, rule-making and initiatives.